Patents have now been granted in more than 30 countries for Nutraceutix’s “Delivery System for Biological Component”, trademarked as BIO-tract®. This now includes the 24 countries in the European Patent Convention, in addition to Australia, Canada, Singapore, Japan, Hong Kong, Republic of Korea, People’s Republic of China, the Russian Federation and the United States. Additional patents in the U.S. and Canada are pending.
The European Patent Convention includes: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, The Netherlands, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.
Unlike powders, capsules and cultured foods, BIO-tract tablets offer protection from damaging stomach acids, then gently release live organisms over time to the upper and lower intestinal tracts for heightened effectiveness. BIO-tract also takes advantage of Nutraceutix’s patented LiveBac® processing to extend probiotic shelf life far beyond other supplemental forms, even at room temperature.
“Our growing, global patent portfolio documents BIO-tract’s technical superiority,” asserts Tim Gamble, president and CEO of Nutraceutix. "For years, BIO-tract has been a recognized hallmark of quality and is now becoming the industry standard for premium probiotics and other ingredients that benefit from its unique capabilities. It is the only probiotic dietary supplement format that offers such a stellar combination of effective delivery and stability with outstanding formulation and packaging flexibility.”